analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
Published 3 years ago • 113 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
1:45
momelotinib vs soc in patients with mf and anemia: an analysis from the simplify-2 trial
-
2:16
long-term safety of momelotinib for myelofibrosis
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
3:12
transfusion independence and momelotinib in myelofibrosis
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
4:25
update on momelotinib for myelofibrosis
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
1:49
phase ii trial-in-progress of itacitinib in patients with myelofibrosis
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
2:07
the current research on momelotinib for myelofibrosis
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
4:39
imetelstat shows promise in advanced myelofibrosis